Warning! GuruFocus detected
1 Severe warning sign
with UNCY.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Unicycive Therapeutics Inc
NAICS : 325110
SIC : 2834
ISIN : US90466Y1038
Share Class Description:
UNCY: Ordinary SharesDescription
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 33.82 | |||||
| Equity-to-Asset | 0.24 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 12.3 | |||||
| 3-Year EPS without NRI Growth Rate | 16.9 | |||||
| 3-Year FCF Growth Rate | 4.8 | |||||
| 3-Year Book Growth Rate | -59.7 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.36 | |||||
| 9-Day RSI | 66.01 | |||||
| 14-Day RSI | 59.75 | |||||
| 3-1 Month Momentum % | 5.23 | |||||
| 6-1 Month Momentum % | 53.16 | |||||
| 12-1 Month Momentum % | -34.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.28 | |||||
| Quick Ratio | 1.28 | |||||
| Cash Ratio | 1.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -90.6 | |||||
| Shareholder Yield % | -0.67 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -217.22 | |||||
| ROA % | -101.17 | |||||
| ROIC % | -206.78 | |||||
| 3-Year ROIIC % | -116.87 | |||||
| ROC (Joel Greenblatt) % | -4952.45 | |||||
| ROCE % | -213.03 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 8.89 | |||||
| Price-to-Tangible-Book | 9.14 | |||||
| EV-to-EBIT | -1.4 | |||||
| EV-to-EBITDA | -1.42 | |||||
| EV-to-Forward-Revenue | 2.54 | |||||
| EV-to-FCF | -1.79 | |||||
| Price-to-Net-Current-Asset-Value | 10.67 | |||||
| Price-to-Net-Cash | 32 | |||||
| Earnings Yield (Greenblatt) % | -71.43 | |||||
| FCF Yield % | -37.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:UNCY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Unicycive Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.999 | ||
| Beta | 2.22 | ||
| 3-Year Sharpe Ratio | 0.3 | ||
| 3-Year Sortino Ratio | 1.01 | ||
| Volatility % | 82.46 | ||
| 14-Day RSI | 59.75 | ||
| 14-Day ATR ($) | 0.048259 | ||
| 20-Day SMA ($) | 0.57297 | ||
| 12-1 Month Momentum % | -34.47 | ||
| 52-Week Range ($) | 0.202 - 1.289 | ||
| Shares Outstanding (Mil) | 119.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Unicycive Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Unicycive Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Unicycive Therapeutics Inc Frequently Asked Questions
What is Unicycive Therapeutics Inc(UNCY)'s stock price today?
The current price of UNCY is $0.64. The 52 week high of UNCY is $1.29 and 52 week low is $0.20.
When is next earnings date of Unicycive Therapeutics Inc(UNCY)?
The next earnings date of Unicycive Therapeutics Inc(UNCY) is 2025-05-13 Est..
Does Unicycive Therapeutics Inc(UNCY) pay dividends? If so, how much?
Unicycive Therapeutics Inc(UNCY) does not pay dividend.
Guru Commentaries on NAS:UNCY
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers